182 related articles for article (PubMed ID: 26517536)
21. Treatment approach to newly diagnosed diffuse large B-cell lymphoma.
Bachy E; Salles G
Semin Hematol; 2015 Apr; 52(2):107-18. PubMed ID: 25805590
[TBL] [Abstract][Full Text] [Related]
22. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
[TBL] [Abstract][Full Text] [Related]
23. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
[TBL] [Abstract][Full Text] [Related]
24. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
25. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
26. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
[TBL] [Abstract][Full Text] [Related]
27. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
Miyazaki K
Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
[TBL] [Abstract][Full Text] [Related]
28. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
29. DLBCL Cell of Origin: What Role Should It Play in Care Today?
Rutherford SC; Leonard JP
Oncology (Williston Park); 2018 Sep; 32(9):445-9. PubMed ID: 30248164
[TBL] [Abstract][Full Text] [Related]
30. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
31. Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature.
Gabeeva NG; Zvonkov EE; Koroleva DA; Chukavina MM; Obukhova TN; Kovrigina AM
Ter Arkh; 2018 Aug; 90(7):96-101. PubMed ID: 30701929
[TBL] [Abstract][Full Text] [Related]
32. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
[TBL] [Abstract][Full Text] [Related]
33. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
Chen Y; Chen H; Fu K; Zhu XZ; Irons R
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma.
Hill BT; Sweetenham J
Leuk Lymphoma; 2012 May; 53(5):763-9. PubMed ID: 21992676
[TBL] [Abstract][Full Text] [Related]
35. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
36. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.
Culpin RE; Proctor SJ; Angus B; Crosier S; Anderson JJ; Mainou-Fowler T
Int J Oncol; 2010 Aug; 37(2):367-76. PubMed ID: 20596664
[TBL] [Abstract][Full Text] [Related]
37. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
38. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
39. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
40. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
